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When I counsel women with babies born with congenital CMV infection, common 
questions include: “why wasn't I told about this infection before I became 
pregnant? If CMV damages so many babies each year, why don't we have a 
screening programme?" 
 
Bodies responsible for deciding if there should be screening for a new condition 
lay down strict criteria. Consistent application of these criteria is designed to 
ensure that screening is only done if it can be shown that benefits will be 
produced that outweigh the financial and opportunity costs that are inevitably 
incurred.(1) It is also important to show that the benefits outweigh the parental 
anxiety that any screening program should be expected to induce. Congenital 
CMV meets all the criteria required except for one: treatment of asymptomatic 
infection.(2, 3) Treatment of neonates has been shown to be effective, but the 
cases recruited were all identified because they had symptoms at birth.(4, 5) 
Although we know that many cases with symptoms are not recognised in routine 
clinical practice, a screening programme should not be created simply to 
compensate for inadequacies in diagnostic skills. 
 
The absence of a screening test means that other linked public health initiatives, 
such as providing information to those at risk, can be left on the back burner. 
Professional bodies can review the issue and conclude, not unreasonably from 
their point of view, that they should only take action once an intervention, like 
treatment or screening, becomes available. This creates a Catch-22, where 
regulators will not allow screening to begin until the treatment of asymptomatics 
has been shown to be safe and effective, while children who are asymptomatic 
cannot be identified in the absence of a screening programme (or an 
unrealistically large research grant). The resulting stalemate has led to some 
frustration, especially as conditions considered more newsworthy, such as Zika 
in pregnancy, seem to acquire immediate support, despite their lower propensity 
for damaging babies in temperate climes.(6) 
 
This impasse has now been disturbed by the birth of Daisy in 2012 who has had 
an effect on public health out of all proportion to her low birth weight. Her 
parents, like many before them, were shocked to discover that a virus able to 
damage large numbers of babies is circulating in our communities without 
women of childbearing age being alerted to the risks and being offered the 
potential to take steps to reduce those risks. The difference in the case of Daisy 
is that her grandmother is a legislator in the US state of Utah. Instantly 
recognising an injustice, she set about framing legislation that would require the 
provision of information about CMV. A bill passed rapidly into law on 1 July 2013 
directs the Utah Department of Health to take two actions. Firstly, to create a 
public education program to inform women of childbearing age about CMV and 
its transmission, the birth defects it can cause, methods of diagnosis, and 
available preventative measures. Secondly, it requires medical practitioners to 
test infants who fail newborn hearing screening tests for the presence of 
congenital CMV. If this can be done rapidly enough, treatment with valganciclovir 
can be started within the first month of life, which is the time cut-off studied in the 
randomised controlled trials that showed clinical benefit.(4, 5) Similar, but not 
identical, laws in Connecticut, Hawaii, Illinois, Texas and Tennessee followed this 
initiative. An additional 8 states now have legislation pending.(7) The message is 
clear; if medical practitioners sit in their professional silos and refuse to take an 
initiative until a cognate professional group makes the first move, then parents 
will see the bigger picture and force change by exerting their constitutional rights 
to have their concerns addressed. 
 
Where does this leave us in Europe as we observe the tide turning in the USA 
towards selective screening of those who fail their newborn hearing tests and, 
potentially, universal screening of all babies? Many innovations that start in North 
America end up reaching these shores along with the prevailing winds. European 
screening committees appear to hold to an overly rigid interpretation of the 
criteria and decline to countenance assessments of whether children and their 
families might benefit from linking laboratory testing for congenital CMV with that 
for newborn hearing screening. This is despite preliminary results indicating both 
efficacy and cost-effectiveness.(8-10) It would equally be possible to interpret the 
prevention of further hearing loss in the randomised controlled trials as adequate 
proof that early treatment can delay or prevent future loss of hearing.(4, 5) This 
would then allow committees to justify initiating a pilot study in one region of a 
country whose results would guide whether nationwide screening could be 
justified. In the absence of such an initiative, screening committees may be 
accused of not doing enough for the ordinary people who have recently 
unleashed a wave of anti-establishment populism in the USA. Thus, committee 
members need to keep an eye on the weather coming from the West lest, like 
King Canute, they soon find themselves left looking somewhat damp. 
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